Lennox-Gastaut Syndrome Treatment Market 2026, Rising Population With Risk Factors For LGS to Boost Growth - Technavio
NEW YORK, Oct. 5, 2022 /PRNewswire/ -- The lennox-gastaut syndrome treatment market size is expected to grow by USD 684.75 million during 2021-2026, at a CAGR of 4.42% during the forecast period, according to Technavio. The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Akron Children's Hospital, Amneal Pharmaceuticals Inc., Aquestive Therapeutics Inc., Cedars-Sinai Health System, Cision Ltd, Eisai Co. Ltd., Epilepsy Foundation, GlaxoSmithKline Plc, Lupin Ltd, Sun Pharmaceutical Industries Ltd, Supernus Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., UCB SA, Upsher Smith Laboratories LLC, Viatris Inc., and Johnson and Johnson are some of the major market participants.
The rising population with risk factors for LGS, growing awareness of LGS, and orphan drug designation will offer immense growth opportunities. However, difficulty in diagnosing LGS, side effects associated with available treatment, and the increasing popularity of generics will challenge the growth of the market participants. Download Free Sample Report.
To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
- Type
- Non-surgical Treatment
- Surgical Treatment
- Geography
- North America
- Europe
- Asia
- Rest Of World (ROW)
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our Lennox-gastaut syndrome treatment market report covers the following areas:
- Lennox-Gastaut Syndrome Treatment Market size
- Lennox-Gastaut Syndrome Treatment Market trends
- Lennox-Gastaut Syndrome Treatment Market industry analysis
This study identifies the introduction of phytochemicals as one of the prime reasons driving the Lennox-gastaut syndrome treatment market growth during the next few years. Buy Sample Report.
We provide a detailed analysis of around 25 vendors operating in the Lennox-Gastaut Syndrome Treatment Market, including some of the vendors such as vendors Backed with competitive intelligence and benchmarking, our research reports on the Lennox-Gastaut Syndrome Treatment Market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
- Akron Children's Hospital
- Amneal Pharmaceuticals Inc.
- Aquestive Therapeutics Inc.
- Cedars-Sinai Health System
- Cision Ltd
- Eisai Co. Ltd.
- Epilepsy Foundation
- GlaxoSmithKline Plc
- Lupin Ltd
- Sun Pharmaceutical Industries Ltd
- Supernus Pharmaceuticals Inc.
- Teva Pharmaceutical Industries Ltd.
Find additional highlights on the growth strategies adopted by vendors and their product offerings, Request Free Sample Report.
- CAGR of the market during the forecast period
- Detailed information on factors that will assist Lennox-gastaut syndrome treatment market growth during the next five years
- Estimation of the Lennox-gastaut syndrome treatment market size and its contribution to the parent market
- Predictions on upcoming trends and changes in consumer behavior
- The growth of the Lennox-gastaut syndrome treatment market
- Analysis of the market's competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of Lennox-gastaut syndrome treatment market vendors
Related Reports:
Stem Cell Umbilical Cord Blood (UCB) Market by End-user and Geography - Forecast and Analysis 2022-2026
Pregabalin Market by Application and Geography - Forecast and Analysis 2022-2026
Lennox-Gastaut Syndrome Treatment Market Scope | |
Report Coverage | Details |
Page number | 120 |
Base year | 2021 |
Forecast period | 2022-2026 |
Growth momentum & CAGR | Accelerate at a CAGR of 4.42% |
Market growth 2022-2026 | $684.75 million |
Market structure | Fragmented |
YoY growth (%) | 3.34 |
Regional analysis | North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution | Europe at 36% |
Key consumer countries | US, Canada, Germany, UK, and China |
Competitive landscape | Leading companies, competitive strategies, consumer engagement scope |
Companies profiled | Akron Children's Hospital, Amneal Pharmaceuticals Inc., Aquestive Therapeutics Inc., Cedars-Sinai Health System, Cision Ltd, Eisai Co. Ltd., Epilepsy Foundation, GlaxoSmithKline Plc, Lupin Ltd, Sun Pharmaceutical Industries Ltd, Supernus Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., UCB SA, Upsher Smith Laboratories LLC, Viatris Inc., and Johnson and Johnson |
Market Dynamics | Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period. |
Customization purview | If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
1 Executive Summary
- 1.1 Market Overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
- Exhibit 06: Executive Summary – Chart on Incremental Growth
- Exhibit 07: Executive Summary – Data Table on Incremental Growth
- Exhibit 08: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 09: Parent market
- Exhibit 10: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 11: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 12: Market segments
- 3.3 Market size 2021
- 3.4 Market outlook: Forecast for 2021-2026
- Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
- Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
4 Five Forces Analysis
- 4.1 Five forces summary
- Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
- 4.2 Bargaining power of buyers
- Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
- 4.3 Bargaining power of suppliers
- Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
- 4.4 Threat of new entrants
- Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
- 4.5 Threat of substitutes
- Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
- 4.6 Threat of rivalry
- Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
- 4.7 Market condition
- Exhibit 23: Chart on Market condition - Five forces 2021 and 2026
5 Market Segmentation by Type
- 5.1 Market segments
- Exhibit 24: Chart on Type - Market share 2021-2026 (%)
- Exhibit 25: Data Table on Type - Market share 2021-2026 (%)
- 5.2 Comparison by Type
- Exhibit 26: Chart on Comparison by Type
- Exhibit 27: Data Table on Comparison by Type
- 5.3 Non-surgical treatment - Market size and forecast 2021-2026
- Exhibit 28: Chart on Non-surgical treatment - Market size and forecast 2021-2026 ($ million)
- Exhibit 29: Data Table on Non-surgical treatment - Market size and forecast 2021-2026 ($ million)
- Exhibit 30: Chart on Non-surgical treatment - Year-over-year growth 2021-2026 (%)
- Exhibit 31: Data Table on Non-surgical treatment - Year-over-year growth 2021-2026 (%)
- 5.4 Surgical treatment - Market size and forecast 2021-2026
- Exhibit 32: Chart on Surgical treatment - Market size and forecast 2021-2026 ($ million)
- Exhibit 33: Data Table on Surgical treatment - Market size and forecast 2021-2026 ($ million)
- Exhibit 34: Chart on Surgical treatment - Year-over-year growth 2021-2026 (%)
- Exhibit 35: Data Table on Surgical treatment - Year-over-year growth 2021-2026 (%)
- 5.5 Market opportunity by Type
- Exhibit 36: Market opportunity by Type ($ million)
6 Customer Landscape
- 6.1 Customer landscape overview
- Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
7 Geographic Landscape
- 7.1 Geographic segmentation
- Exhibit 38: Chart on Market share by geography 2021-2026 (%)
- Exhibit 39: Data Table on Market share by geography 2021-2026 (%)
- 7.2 Geographic comparison
- Exhibit 40: Chart on Geographic comparison
- Exhibit 41: Data Table on Geographic comparison
- 7.3 North America - Market size and forecast 2021-2026
- Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
- Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)
- 7.4 Europe - Market size and forecast 2021-2026
- Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
- Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
- 7.5 Asia - Market size and forecast 2021-2026
- Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
- Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
- 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
- Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- 7.7 US - Market size and forecast 2021-2026
- Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
- Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)
- 7.8 Germany - Market size and forecast 2021-2026
- Exhibit 62: Chart on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 63: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 64: Chart on Germany - Year-over-year growth 2021-2026 (%)
- Exhibit 65: Data Table on Germany - Year-over-year growth 2021-2026 (%)
- 7.9 Canada - Market size and forecast 2021-2026
- Exhibit 66: Chart on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 67: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 68: Chart on Canada - Year-over-year growth 2021-2026 (%)
- Exhibit 69: Data Table on Canada - Year-over-year growth 2021-2026 (%)
- 7.10 UK - Market size and forecast 2021-2026
- Exhibit 70: Chart on UK - Market size and forecast 2021-2026 ($ million)
- Exhibit 71: Data Table on UK - Market size and forecast 2021-2026 ($ million)
- Exhibit 72: Chart on UK - Year-over-year growth 2021-2026 (%)
- Exhibit 73: Data Table on UK - Year-over-year growth 2021-2026 (%)
- 7.11 China - Market size and forecast 2021-2026
- Exhibit 74: Chart on China - Market size and forecast 2021-2026 ($ million)
- Exhibit 75: Data Table on China - Market size and forecast 2021-2026 ($ million)
- Exhibit 76: Chart on China - Year-over-year growth 2021-2026 (%)
- Exhibit 77: Data Table on China - Year-over-year growth 2021-2026 (%)
- 7.12 Market opportunity by geography
- Exhibit 78: Market opportunity by geography ($ million)
8 Drivers, Challenges, and Trends
- 8.1 Market drivers
- 8.2 Market challenges
- 8.3 Impact of drivers and challenges
- Exhibit 79: Impact of drivers and challenges in 2021 and 2026
- 8.4 Market trends
9 Vendor Landscape
- 9.1 Overview
- 9.2 Vendor landscape
- Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
- 9.3 Landscape disruption
- Exhibit 81: Overview on factors of disruption
- 9.4 Industry risks
- Exhibit 82: Impact of key risks on business
10 Vendor Analysis
- 10.1 Vendors covered
- Exhibit 83: Vendors covered
- 10.2 Market positioning of vendors
- Exhibit 84: Matrix on vendor position and classification
- 10.3 Cedars-Sinai Health System
- Exhibit 85: Cedars-Sinai Health System - Overview
- Exhibit 86: Cedars-Sinai Health System - Business segments
- Exhibit 87: Cedars-Sinai Health System - Key offerings
- Exhibit 88: Cedars-Sinai Health System - Segment focus
- 10.4 Cision Ltd
- Exhibit 89: Cision Ltd - Overview
- Exhibit 90: Cision Ltd - Product / Service
- Exhibit 91: Cision Ltd - Key offerings
- 10.5 Eisai Co. Ltd.
- Exhibit 92: Eisai Co. Ltd. - Overview
- Exhibit 93: Eisai Co. Ltd. - Business segments
- Exhibit 94: Eisai Co. Ltd. - Key offerings
- Exhibit 95: Eisai Co. Ltd. - Segment focus
- 10.6 Epilepsy Foundation
- Exhibit 96: Epilepsy Foundation - Overview
- Exhibit 97: Epilepsy Foundation - Product / Service
- Exhibit 98: Epilepsy Foundation - Key offerings
- 10.7 GlaxoSmithKline Plc
- Exhibit 99: GlaxoSmithKline Plc - Overview
- Exhibit 100: GlaxoSmithKline Plc - Business segments
- Exhibit 101: GlaxoSmithKline Plc - Key news
- Exhibit 102: GlaxoSmithKline Plc - Key offerings
- Exhibit 103: GlaxoSmithKline Plc - Segment focus
- 10.8 Johnson and Johnson
- Exhibit 104: Johnson and Johnson - Overview
- Exhibit 105: Johnson and Johnson - Business segments
- Exhibit 106: Johnson and Johnson - Key news
- Exhibit 107: Johnson and Johnson - Key offerings
- Exhibit 108: Johnson and Johnson - Segment focus
- 10.9 Supernus Pharmaceuticals Inc.
- Exhibit 109: Supernus Pharmaceuticals Inc. - Overview
- Exhibit 110: Supernus Pharmaceuticals Inc. - Product / Service
- Exhibit 111: Supernus Pharmaceuticals Inc. - Key offerings
- 10.10 Teva Pharmaceutical Industries Ltd.
- Exhibit 112: Teva Pharmaceutical Industries Ltd. - Overview
- Exhibit 113: Teva Pharmaceutical Industries Ltd. - Business segments
- Exhibit 114: Teva Pharmaceutical Industries Ltd. - Key news
- Exhibit 115: Teva Pharmaceutical Industries Ltd. - Key offerings
- Exhibit 116: Teva Pharmaceutical Industries Ltd. - Segment focus
- 10.11 UCB SA
- Exhibit 117: UCB SA - Overview
- Exhibit 118: UCB SA - Product / Service
- Exhibit 119: UCB SA - Key offerings
- 10.12 Upsher Smith Laboratories LLC
- Exhibit 120: Upsher Smith Laboratories LLC - Overview
- Exhibit 121: Upsher Smith Laboratories LLC - Product / Service
- Exhibit 122: Upsher Smith Laboratories LLC - Key offerings
11 Appendix
- 11.1 Scope of the report
- 11.2 Inclusions and exclusions checklist
- Exhibit 123: Inclusions checklist
- Exhibit 124: Exclusions checklist
- 11.3 Currency conversion rates for US$
- Exhibit 125: Currency conversion rates for US$
- 11.4 Research methodology
- Exhibit 126: Research methodology
- Exhibit 127: Validation techniques employed for market sizing
- Exhibit 128: Information sources
- 11.5 List of abbreviations
- Exhibit 129: List of abbreviations
- in the incidence rate
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download multimedia:https://www.prnewswire.com/news-releases/lennox-gastaut-syndrome-treatment-market-2026-rising-population-with-risk-factors-for-lgs-to-boost-growth---technavio-301640564.html
SOURCE Technavio
Upcoming Life Sciences Events
- April 2024
- London: BioTrinity 2024
- Singapore: Asia Bio Partnering Forum
- London: LSX World Congress